
CDISC-Compliant Dataset Generation
Submission-Ready Datasets. Zero Rejections.
Achieve Compliance
Wemedoo provides end-to-end CDISC-compliant dataset generation and documentation, transforming clinical data into complete submission packages for regulatory review. We deliver SDTM, SEND, ADaM datasets, Define.XML files, and supporting documents — ensuring accuracy, validation, and efficiency through our expert team of data managers, biostatisticians, and medical writers.
End-to-End CDISC Dataset Generation & Documentation
Our Proof of Quality
We are ISO 9001 and ISO 27001 certified. Our commitment to robust information security & superior quality management is at the core of our innovative solutions, ensuring reliable & efficient trial management for our clients.

Main Areas of CDISC-Compliant Dataset Generation & Documentation
We transform clinical trial data into regulatory-ready formats with tailored solutions. Our streamlined process covers annotated CRFs, SDTM/SEND, ADaM databases, Define.XML metadata, validation checks, and CDISC-compliant submission documents. We ensure full regulatory compliance (FDA, PMDA, NMPA) to support investigators, data managers, and research teams throughout the trial.
Annotated CRFs are an essential CDISC regulatory submission deliverable, dictating the contents of SDTM/SEND databases. Wemedoo's clinical data management and statistical programmers work together in creating study CRFs and their CDISC annotations in parallel, expediting the process for you. Our well-trained team ensures swift and precise aCRF development, consistently meeting both regulatory and industry requirements with efficiency and excellence.
Trusted partners
Global network of partners
Benefits of Our Service
Wemedoo’s collaborative team of data managers, biostatisticians, and medical writers delivers complete CDISC-compliant datasets and documentation services—from annotated CRFs to SDTM/SEND, ADaM, Define.XML, and reviewer guides. Rely on our dedicated experts to simplify submission prep and ensure smooth, compliant regulatory submissions.
Harness the Potential of Precise Dataset Generation & Documentation
Standardized Data Formats
Our service facilitates the use of SDTM and ADaM, the industry-standard data models, to enhance the consistency and quality of clinical trial data generated.
Efficient Review Process
We help streamline the data review process for regulatory authorities, thanks to the well-structured and clearly defined datasets provided by our service.
Accurate Data Mapping
Our service offers precise and effective conversion of clinical trial data into standardized formats, minimizing errors during the process.
Enhanced Data Transparency
We provide a comprehensive and clear understanding of the trial data and analysis methodologies through Define.XML, promoting transparency throughout the research process.
Looking for Clinical Trial Support That Fits Your Study?
Explore how our flexible, integrated services can help you accelerate timelines, improve quality, and reduce complexity.
Frequently Asked Questions
Get the answers you need about our CDISC-compliant service
What types of regulatory submissions does Wemedoo support with CDISC standards?
Our services cover a wide range of regulatory submissions, including those to the FDA, PMDA, and NMPA. Whether it's for new drug applications, investigational new drug submissions, or post-marketing activities, we ensure that your data aligns with CDISC standards for regulatory compliance.
Can Wemedoo outline the steps involved in creating a CDISC regulatory submission package for clinical trial data?
The process typically involves CRF creation, data collection, SDTM/SEND data mapping and creation of databases and their metadata specification, ADaM dataset creation and their metadata specification, Define.XML generation, SDTM/SEND/ADaM/Define.XML validation, and the creation of study data and analysis data reviewer’s guides. Typically, most of these steps occur simultaneously, all thanks to our well connected team of experts – clinical data managers, biostatisticians, and medical writers. Our goal is to provide a comprehensive, well-organized CDISC submission package that ensures a smooth regulatory review process.
How does Wemedoo handle discrepancies or issues identified during the CDISC submission package creation process?
Our process includes thorough quality checks at each stage by multiple experts from different departments, making it transparent and easy to quickly identify discrepancies. We foster open communication both within our company and with the client in resolving any issues.
How does Wemedoo handle updates and changes in CDISC standards over time?
We stay up-to-date with the latest developments in CDISC standards and regulatory requirements. Our team is proactive in implementing updates and changes, ensuring that your data remains current and compliant. We work closely with clients to navigate any transitional phases, providing support and guidance throughout the process.
Does Wemedoo ensure data security and confidentiality during the CDISC-regulated submission process?
We prioritize data security and confidentiality throughout our processes. Our company adheres to industry best practices and internal standards of practice to safeguard your sensitive clinical trial data. We employ encryption, access controls, and secure data transfer protocols to protect information at every stage of the submission deliverables creation process, ensuring the integrity and confidentiality of your data.
Wondering How It All Works?
Learn more about how we can support your clinical trials.
SPEAK TO AN EXPERTExplore Related Services
Beyond protocol development, Wemedoo offers a comprehensive suite of integrated data operations services for clinical trials. At each step, we ensure your trial meets the highest quality and regulatory standards, while streamlining your clinical trial processes and saving you time and money. Discover our other services, all focusing on innovation and excellence in clinical research.
Proud to be a Member of CDISC
Since November 2020, we have been a part of the Clinical Data Interchange Standards Consortium. It is our concern to improve the quality and efficiency of clinical research.
Resources
CDISC resources
CDISC Compliant Dataset Generation
Wemedoo returns to Xraised episode 2 with unified data in focus
July 9, 2026
Artificial Intelligence in Clinical Trials: Balancing Innovation and Accuracy
June 24, 2026
A new scientific publication featuring Wemedoo researchers has been published in BMC Medical Research Methodology
June 24, 2026
Interoperability: The Missing Piece in Clinical Trial Efficiency
June 24, 2026
Mastering Protocol Deviation Management: The Smart Way Forward With ePDL
June 24, 2026
The CRO’s Guide to Winning Sponsor Trust
June 24, 2026
Key Takeaways from EUCROF25: AI, Integration, and CRO Challenges in Clinical Trials
June 24, 2026
Wemedoo Becomes an Associate Member of EUCROF
June 24, 2026
Across Global Alliance Selects oomnia as a Central Trial Infrastructure
June 24, 2026
Revolutionizing Clinical Trials: How Wemedoo is Accelerating Global Research
June 24, 2026
Why does unified data matter? Hear from Wemedoo at Swiss Biotech Day!
June 24, 2026
Wemedoo in The CEO Magazine: Fixing Clinical Trials
June 24, 2026
Wemedoo in Forbes: From Clinical Frustration to Real Innovation
June 24, 2026
New Era of Clinical Trials with oomnia®: Built for Complexity, Designed for Simplicity
June 24, 2026
From consent to compliance in patient-centric clinical trials
June 24, 2026
Reducing costs and standing out as a CRO
June 24, 2026
Dr. Nikola Cihoric elected to EUCROF AI Expert Group
June 24, 2026
Wemedoo announces strategic partnership with mediri to streamline imaging data management in clinical trials
June 24, 2026
Wemedoo’s innovation journey with oomnia on Xraised
June 24, 2026
Accessing better technology for clinical trials
June 24, 2026
The hidden cost of disconnected systems in biotech and the path to streamlined trials
June 24, 2026
Wemedoo receives SCDM innovator start-up of the year 2025 award
June 24, 2026
From device to database in 2 weeks made possible by Wemedoo and Withings
June 24, 2026
Wemedoo featured on BioSpace
June 24, 2026
Wemedoo joins Xraised again to share new perspectives
June 24, 2026
Wemedoo featured on AP News
June 24, 2026
Clinical trial trends in 2025
June 24, 2026
Why eClinical architectures have reached their limits, and a new category is emerging
June 24, 2026
Handling complex data in oncology trials
June 24, 2026
Fast database lock in a complex Phase III diabetes study
June 24, 2026
Why compliance risk increases in modular eClinical setups
June 24, 2026
The system architecture behind the data reconciliation challenge in clinical trials
June 24, 2026
What makes a clinical trial software truly unified
June 24, 2026
Solving MedTech trial complexity with the right technology partner
June 24, 2026
Top EDC software solutions for clinical trial teams
June 24, 2026
oomnia - Meeting Industry Standards
Our unified clinical trial software is designed with compliance at its core, meeting critical industry standards. Our commitment to these regulations ensures that your clinical trials are not only efficient but also adhere to the highest levels of data integrity, privacy, and ethical conduct.
See What Our Clients Say
Read more about the experiences from those who have partnered with us
All jobs, both large and small, are performed with the same dedication to quality, detail, innovative thinking, and rigor. It is always a pleasure to work with the Wemedoo team.
Georg Mathis, PhD
CEO Appletree CI Group AG
Wemedoo embodies all the traits desired in a partner in the clinical trial industry – expertise, innovation, reliability, compliance, and attention to detail.
Martina Diminic Smetisko, DMD
Managing Director at Marti Farm Ltd
Their dedication to, and support of, our projects has resulted in clear quality deliverables. They are always there to answer any questions with expertise in a timely manner. I am...
Their dedication to, and support of, our projects has resulted in clear quality deliverables. They are always there to answer any questions with expertise in a timely manner. I am looking forward to our next project together.
Volodymyr Stus, MD
Biopharmaceutics and Clinical Research Department Manager at Polpharma SA
Wemedoo's cross-functional, integrated teams capture EDC set-up, go-live, data capture, data cleaning, and finally data analysis in a globally compliant fashion supporting trials in different geographies including the US. Their...
Wemedoo's cross-functional, integrated teams capture EDC set-up, go-live, data capture, data cleaning, and finally data analysis in a globally compliant fashion supporting trials in different geographies including the US. Their speed of addressing customer needs sets in my personal experience industry benchmark whilst keeping these data solutions lean and affordable. Besides the great proprietary systems they use, their integrated team approach with personal responsibility and honest commitment to targeting outcomes differentiates the Wemedoo team from other providers. Wemedoo only made Oxular's key initial trial, a device-drug trial possible, as based on some pre-work, the Wemedoo team could substantially adapt and update the first EDC ideas for a trial under a US FDA IND. The Wemedoo team worked extremely focused on familiarizing US trial sites and clinical CROs with the use of their system, which turned out to be a key success factor of the respective trial. The highly professional and up-to-date capabilities in data sciences were mirrored by customer-centricity and super fast timelines of integrating mandatory adaptations to the data systems.
Friedrich Asmus, MD
Chief Medical Officer at Oxular
Wemedoo's technology, expertise, and intimate engagement with our team in the development of the EDC, site/patient interface, and metric capabilities are unique. They provided insight and challenged the underlying assumptions...
Wemedoo's technology, expertise, and intimate engagement with our team in the development of the EDC, site/patient interface, and metric capabilities are unique. They provided insight and challenged the underlying assumptions to ensure the study's goals and objectives were clearly defined and the operating structure matched with the study's intent. Their system is not a one-size-fits-all and they adapt to the needs of the sponsor, sites, physicians, and the study requirements into a system that merges health information/data and can then become not only informative but actionable.
James Kuras
Vice President of Clinical Affairs and Operations at CENTINEL SPINE
Considering Unified Clinical Trial Software?
Experience oomnia, our all-in-one clinical trial software which unifies tools, such as EDC, eSource, RTSM, eTMF, ePRO, eCOA, eConsent, and CTMS. In combination with our professional services, we can provide end-to-end support to transform your clinical research.
BOOK A DEMO